Skip to main content

Profiling Responders In Antibody Therapies

Cel

"Therapeutic antibodies are the largest and fastest growing class of pharmaceutical biotechnology products, with annual sales above 30 billion US$. In some cases, antibody products have revolutionized the management of patients, e.g. TNF-blocking antibodies in Arthritis or Rituxan in lymphoma. However, for most antibody therapies, only a subset of patients benefit from treatment. Thus, there is an urgent need to develop more potent therapeutic antibodies and to understand the molecular basis for the differential responses of patients to treatment.
This consortium consists of European centres of excellence being pioneers in the field of therapeutic antibody development and (pre-) clinical studies and will tackle both of these challenges:
Innovative immunocytokines L19-IL2 and F8-IL10 are developed by Philogen for the treatment of metastatic melanoma and rheumatoid arthritis respectively at multiple clinical centres including Graz and Tübingen.
Building on the strong background in proteomics biomarker discovery of ETH Zurich and Philochem, an innovative methodology (“HLA-peptidome analysis”) will be utilized for gaining information on the immune response in animal models and patients which receive antibody treatments. This method is based on the observation that HLA molecules in complex with peptides can be detected in the patient blood and that hundreds of HLA-associated peptides can be sequenced by mass spectrometry. The technology will be used for the profiling of responses following antibody treatment for patients with cancer and rheumatoid arthritis, as well as animal models of transplant rejection. This systems biology approach has the potential to revolutionize patient stratification in very short time.
Finally, patient selection strategies will be investigated using the clinical-grade immunocytokine (F8-IL10) as an example, monitoring antibody uptake at the site of disease by immuno-PET imaging methodologies at VUMC Amsterdam in collaboration with Philogen."

Zaproszenie do składania wniosków

FP7-HEALTH-2012-INNOVATION-1
Zobacz inne projekty w ramach tego zaproszenia

Koordynator

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
Adres
Raemistrasse 101
8092 Zuerich
Szwajcaria
Rodzaj działalności
Higher or Secondary Education Establishments
Wkład UE
€ 539 987
Kontakt administracyjny
Dario Neri (Prof.)

Uczestnicy (7)

PHILOGEN SPA
Włochy
Wkład UE
€ 304 980
Adres
Piazza La Lizza 7
53100 Siena
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt administracyjny
Chiara Falciani (Dr.)
PHILOCHEM AG
Szwajcaria
Wkład UE
€ 755 028
Adres
Wolfgang Pauli Strasse 10
8093 Zurich
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt administracyjny
Tim Fugmann (Dr.)
STICHTING VU
Niderlandy
Wkład UE
€ 383 034
Adres
De Boelelaan 1105
1081 HV Amsterdam
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Gerard Hoskens (Dr.)
Universitätsklinikum Jena
Niemcy
Wkład UE
€ 286 260
Adres
Bachstraße 18
07740 Jena
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Marcus Franz (Dr.)
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Niemcy
Wkład UE
€ 206 460
Adres
Geschwister-scholl-platz
72074 Tuebingen
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Claus Garbe (Prof.)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
Wkład UE
€ 285 276
Adres
Wellington Square University Offices
OX1 2JD Oxford
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Linda Pialek (Ms.)
Medizinische Universitaet Graz
Austria
Wkład UE
€ 206 460
Adres
Auenbruggerplatz 2
8036 Graz
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Thomas Korenjak (Mr.)